SRC
CORT icon

Sage Rhino Capital’s Corcept Therapeutics CORT Stock Holding History

Sage Rhino Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
+3,048
New +$184K 0.04% 250
2025
Q4 		– Sell
-2,991
Closed -$249K – 318
2025
Q3 		$249K Buy
2,991
+28
+0.9% +$2.03K 0.05% 220
2025
Q2 		$217K Sell
2,963
-237
-7% -$17.2K 0.05% 225
2025
Q1 		$366K Buy
+3,200
New +$195K 0.08% 152

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sage Rhino Capital's CORT Position: Q2 2026 in Review

Sage Rhino Capital opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,048 shares worth $265K. The stake represents 0.04% of the portfolio and ranks #250 among its holdings. This is a return to the name: Sage Rhino Capital previously reported a position in CORT as recently as Q3 2025.

Sage Rhino Capital first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. The position peaked at $366K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Sage Rhino Capital held 3,048 shares of Corcept Therapeutics worth $265K as of Q2 2026.
  • Corcept Therapeutics was a new Sage Rhino Capital position in Q2 2026.
  • Corcept Therapeutics made up 0.04% of Sage Rhino Capital's portfolio in Q2 2026, its #250 holding.
  • Sage Rhino Capital first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Sage Rhino Capital's Corcept Therapeutics position peaked at $366K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.